A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia
Status:
Suspended
Trial end date:
2029-05-01
Target enrollment:
Participant gender:
Summary
To find the recommended dose of the study drugs ASTX727 and ASTX029 that can be given to
patients with relapsed/refractory AML. The goal of Part 2 of the study is to learn if the
dose of study drugs found in Part 1B can help to control AML.